| Authors: |
Vianna P; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Chakraborty R; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Hossain S; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Bhutani D; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Miller S; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Rossi A; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Cuddy SAM; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Falk RH; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Lentzsch S; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Laubach JP; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Bianchi G; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA. |
